In contrast, in patients with CLL, the increase was 3.28-fold for CD4+TLR2+, 3.07-fold for CD8+TLR2+, and 4.75-fold for CD19+TLR2+ relative to the control group (Figure 4) (Table 3). This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.